 Provider News CaliforniaApril 2024 Provider Newsletter Contents
CABC-CDCRCM-053234-24 HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA). Effective for all claims received on and after May 1, 2024, Anthem is updating its outpatient facility editing system to align with correct coding guidelines. As a result, claims billed with HCPCS/CPT® codes 0373T, 0362T, 90853, 90887, 96121-96171, 97151-97158, 90785, 90791, 90792, 90832-90847, 90863, H0001-H2035, S0201, S9480, and an inappropriate revenue code(s) will be denied. For assistance with coding guidelines, please refer to CPT Coding Guidelines or Encoder Pro. If you believe you have received a denial in error, please follow the standard claim dispute process for Anthem. Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross and Anthem Blue Cross Life and Health Insurance Company are independent licensees of the Blue Cross Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. CABC-CM-052164-24 Anthem uses post-pay and prepayment review in certain circumstances to validate the appropriate level for facility emergency department (ED) claims. This process identifies the level of ED E&M code by intensity and/or complexity of resources or interventions a facility uses to furnish all services indicated on the claim. Providers must use appropriate HIPAA-compliant codes for all services rendered during the ED encounter. The highest intervention/resource used will determine the final facility ED level. Anthem defines: - Interventions: the staff the facility uses and their work performed
- Resources: facility building, equipment, and/or supplies used
Note: Professional provider services are not considered facility interventions or resources. - Intensity and/or complexity: quantity, type, or specialization of interventions and/or resources used and the nature of the presenting problem, member age, acuity, and diagnostic services performed, as indicated on the claim
- Emergency services: a medical condition manifesting itself by acute symptoms of recent onset and sufficient severity (including severe pain) such that a prudent layperson, who possesses an average knowledge of health and medicine, could reasonably expect the absence of immediate medical care, could result in (a) placing the health of an individual in serious jeopardy, (b) serious impairment to bodily function, (c) serious dysfunction of any bodily organ or part, (d) serious disfigurement, or (e) in the case of a pregnant woman, serious jeopardy to the health of the woman or her unborn child
** In the event a determination cannot be made based on the guidance in this document, a referral to a medical director for a determination will be made. CPT® 99281/HCPCS G0380 Straight forward complexity | The presenting problem(s) are self-limited or minor conditions with no medications or home treatment required, signs and symptoms of wound infection explained, return to ED if problems develop. | Facility intervention | Clinical examples | Triage only | Insect bite (uncomplicated) | No medication or treatment | Read Tb test | Wound recheck | | Steri-Strip wound | | Booster or follow up immunization—no acute injury | | Dressing change (uncomplicated) | | Prescription refill | | Suture removal (uncomplicated) | |
CPT 99282/HCPCS G0381 Low complexity | The presented problem(s) are of low to moderate severity. Over the counter (OTC) medications or treatment, simple dressing changes; patient demonstrates understanding quickly and easily. | Facility intervention | Clinical examples | Simple trauma — up to one x-ray procedure | Localized skin rash, lesion, sunburn | Cast removal | Minor viral infection | Visual acuity exam (Snellen) | Eye discharge — painless | Basic specimen testing: Accucheck, dipstick, UA clean catch | Urinary frequency without fever | I&D of simple abscess | Ear pain (otitis media, sinusitis, vertigo, swimmer's ear, TMJ) | Venipuncture of lab | Dental pain | Simple cultures (throat, skin, urine, wound) | Epistaxis — no packing | Simple laceration/abrasion repair (with Dermabond, without sutures) | Assisting MD with any exam | Simple removal of foreign body without incision or anesthetic | | Apply ace wrap or sling | | Prep or assist with procedures such as minor laceration repair | | Simple burn treatment (first or second degree) | | OTC medication administered | | EKG | |
CPT 99283/HCPCS G0382 Moderate complexity | The presented problem(s) are of moderate severity. Head injury instructions, crutch training, bending, lifting, weight-bearing limitations, prescription medication with review of side effects and potential adverse reactions; patient may have questions, but otherwise demonstrates adequate understanding of instructions either verbally or by demonstration. | Facility intervention | Clinical examples | Nebulizer treatment (two or less) | Headache (simple) — history of, no serial exam | Oxygen therapy | Head injury - without neurologic symptoms | Access port catheter | Cellulitis | Heparin/saline lock | Abdominal pain (simple) | IV push medication | Minor trauma (with potential complicating factors) | IV fluids without medication | Medical conditions requiring prescription drug management | IM or Sub-Q medication administration | Fever which responds to antipyretics | Ear or eye irrigation | Eye pain (corneal abrasion or infection, blepharitis, iritis) | Foley catheter insertion | Non-confirmed overdose | Doppler assessment | Mental health — anxious, simple treatment | Prescription medication administer — PO | Mild dyspnea - not requiring oxygen | Fluorescein stain | Fissure or hemorrhoid | Prep or assist with procedures such as joint aspiration/injection, simple, fracture care, etc. | Epistaxis with packing | X-ray of two or more body areas or two or more x-ray procedures (not above and below joint of same limb) | Assault without radiological testing | | Psychotic patient with no imminent danger to self or others which includes social worker or behavioral health clearance. | | Emesis/Incontinence care | | Postmortem care | | Simple dislocation of patella, finger, or toes without fracture | | Sprain — unable to bear weight | | Routine trach care |
CPT 99284/HCPCS G0383 Moderate-high complexity | The presented problem(s) are of high severity and require urgent evaluation by the physician but do not pose an immediate significant threat to life or physiologic function. Head injury instructions, crutch training, bending, lifting, weight-bearing limitations, prescription medication with review of side effects and potential adverse reactions; patient may have questions, but otherwise demonstrates adequate understanding of instructions either verbally or by demonstration. | Facility intervention | Clinical examples | Blood transfusion | Headache — (complex) or with nausea and vomiting | Insertion of nasal/oral airway | Head injury with LOC | Special imaging study (CT, MRI, Ultrasound, VQ scan) | Chest pain (simple) or with limited diagnostic testing | Cardiac monitoring (external) | Respiratory distress | Administration and monitoring of infusion or parental medications (IV, IM, IO, SC) (Not for immunization administration) | Blunt/penetrating trauma with limited diagnostic testing | Insertion of NG or PEG tube placement, or replacement with multiple reassessments | Dehydration requiring treatment | Prep or assist with procedures such as” Irrigation of eye with Morgan lens, complex laceration repair | Dyspnea with oxygen treatment | Irrigation of bladder with three-way foley catheter | Neurological symptoms: slurred speech, staggered walking, paralysis or numbness of face, arm or leg, or blurred vision in one or both eyes | Change trach tube | Psychotic patient requiring medications in ED with no imminent danger to self or others | EKG x two or more | Care of a confused, combative patient | | Change in mental status of patient |
CPT 99285/HCPCS G0384 High complexity | The presented problem(s) are of high severity and pose an immediate significant threat to life or physiologic function. Multiple prescription medications and/or home therapies with review of side effects and potential adverse reactions; diabetic, seizure, or asthma teaching in compromised or non-compliant patients; patient/caregiver may demonstrate difficulty understanding instructions and may require additional directions to support compliance with prescribed treatment. | Facility intervention | Clinical examples | Cardiac monitoring (invasive) | Chest pain (cardiac) | Multiple IV administrations, does not include fluid administration, and at least one diagnostic imaging study with IV contrast. | Active GI bleed — excluding fissure and hemorrhoid | Physical or chemical restraints | Severe respiratory distress | Fracture reduction or relocation | Epistaxis (complex) | Endotracheal or trach tube insertion | Blunt/penetrating trauma with multiple diagnostic testing required | Endoscopy | Systemic multi-system medical emergency requiring multiple diagnostics | Thoracentesis or paracentesis | Severe infections requiring IV/IM antibiotics | Conscious sedation | Uncontrolled diabetes — blood sugar level at 300 or higher and exhibiting complications like DKA and or unstable vital signs or HHNK | Decontamination for isolation, hazardous material | Severe burns — (level 3 or 4) | Precipitous delivery in ER | Hypothermia | Nebulizer treatments — three or more (If Nebulizer is continuous, each 20-minute period is considered one treatment) | New onset altered mental status | PICC Insertion | Headache (severe) | Lumbar puncture | Major musculoskeletal injury | Sexual Assault Exam with specimen collection by ED staff | Acute peripheral vascular compromise of extremities | Coordination of hospital admission (inpatient or observation) or transfer or change in living situation or site | Toxic ingestions | More than one imaging study (CT, MRI, Ultrasound, VQ scan) combined with multiple different types of departmental tests (lab, EKG, x-ray) | Suicidal or homicidal patient with risk to self or others | Elevated D-dimer that leads to single special imaging study, for example, CT scan | Sexual assault exam with specimen collection | | Abdominal pain (complex) |
Reference and research material | Developed through the consideration of the American College of Emergency Physicians ED Facility Level Coding Guidelines. Revised: April 14, 2022 |
For specific administrative policy details, visit anthem.com/provider/forms and select your state. Through our efforts, we are committed to reducing administrative burden and ensuring timely payments because we value you, our care provider partners. Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross and Anthem Blue Cross Life and Health Insurance Company are independent licensees of the Blue Cross Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. CABC-CM-052452-24 Please review your online provider directory information on a regular basis to ensure it is correct. Access your online provider directory information by visiting anthem.com/ca/provider, then at the top of the webpage, choose Find Care. Review your information and let us know if any of your information in our online directory has changed. Updating your informationAnthem uses the provider data management (PDM) capability available on Availity Essentials to update your provider or facility data. Using the Availity PDM capability meets the quarterly attestation requirement to validate provider demographic data set by the Consolidated Appropriations Act (CAA). PDM features include: - Updating provider demographic information for all assigned payers in one location.
- Attesting to and managing current provider demographic information.
- Monitoring submitted demographic updates in real-time with a digital dashboard.
- Reviewing the history of previously verified data.
Accessing the PDM applicationLog on to Availity.com and select My Providers > Provider Data Management to begin using PDM. Administrators will automatically be granted access to PDM. Additional staff may be given access to PDM by an administrator. To find your administrator, go to My Account Dashboard > My Account > Organization(s) > Administrator Information. PDM trainingPDM training is available: - Learn about and attend one of our training opportunities by visiting here.
- View the Availity PDM quick start guide here.
- Roster automation standard template and roster automation rules of engagement specific training:
- Listen to our recorded webinar here.
Not registered for Availity Essentials yet? If you aren’t registered to use Availity Essentials, signing up is easy and 100% secure. There is no cost for providers to register or to use any of our digital applications. Start by going to Availity.com and selecting New to Availity? Get Started at the top of the home screen to access the registration page. If you have more than one tax ID number (TIN), please ensure you have registered all TINs associated with your account. If you have questions regarding registration, reach out to Availity Client Services at 800-AVAILITY. We are excited for genuine collaboration with you, our care provider partners. Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross and Anthem Blue Cross Life and Health Insurance Company are independent licensees of the Blue Cross Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. CABC-CM-053020-24 As of March 1, 2024, Anthem no longer supports the CAPhysicianApp@anthem.com and CABHContracting@anthem.com email addresses used by providers to request the status of their application to the Anthem network. Providers will instead be referred to Availity Essentials. To check the status of your application, log into Availity. You will find updated information regarding your application in real time under the section, My Dashboard. If you have questions related to Availity Essentials, contact Availity Client Services at 800-282-4548, or visit the Availity support community. If you cannot find the answers to your questions there, visit the Contact Us webpage on anthem.com/ca/provider where you will find answers to everyday questions and departments ready to assist you. With your help, we can continually build towards a future of shared success. Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross and Anthem Blue Cross Life and Health Insurance Company are independent licensees of the Blue Cross Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. CABC-CM-052688-24 To help inform referrals and placements, we are asking all home health agencies to complete this survey, which will allow us to have the most up-to-date information about your agency and allow us to provide the best possible service to you and to our members. Please complete the survey here. It should only take about 10 minutes of your time. With your help, we can continually build towards a future of shared success. Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross and Anthem Blue Cross Life and Health Insurance Company are independent licensees of the Blue Cross Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. CABC-CM-050922-24-CPN50606 We strive to advance health equity so everyone has a fair opportunity to be at their healthiest. As we reduce barriers to whole health — physical, behavioral, and social — and personalize the healthcare journey, we can more effectively advance health equity. While focusing on understanding member needs, we actively develop educational tools for care providers. In recognition of the American Heart Association designating April as National Minority Health Month and Stress Awareness Month, we are featuring two Continuing Medical Education (CME) courses offered in a comprehensive repository of resources on My Diverse Patients. The site is designed to help care providers support the needs of diverse patients and address healthcare disparities. For the month of April, our featured eLearning experiences are: - Reducing Health Care Stereotype Threat — course benefits:
- Understand Health Care Stereotype Threat (HCST) and its implications for multicultural patient groups.
- Learn to recognize when patients may be experiencing HCST.
- Explore shifts that you can make to reduce the likelihood that patients from diverse groups will experience HCST.
- Identify the benefits of reducing HCST to both your patients and your practice.
- Medication Adherence — course benefits:
- Recognize potential barriers to medication adherence and what influences your patients’ thoughts and emotions.
- Understand the importance of meeting your patients where they are, and not where you want them to be.
- Learn how to navigate and break through barriers with C.A.R.E.
These courses are designed for: doctors (CME credit provided); nurses; health professionals; and medical office staff. Providers can view these courses on their smartphone, tablet, or computer. Through genuine collaboration, we can simplify access to care and help you deliver high-quality, equitable healthcare. Anthem Blue Cross is the trade name of Blue Cross of California. Anthem BC Health Insurance Company is the trade name of Anthem Insurance Companies, Inc. Anthem Blue Cross, Anthem Blue Cross Life and Health Insurance Company, Anthem BC Health Insurance Company, and Blue Cross of California Partnership Plan, Inc. are independent licensees of the Blue Cross Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.
Blue Cross of California is contracted with L.A. Care Health Plan to provide Medi-Cal Managed Care services in Los Angeles County. MULTI-ALL-CDCRCM-052951-24-CPN52169 Blue High Performance NetworkSM (BlueHPNSM) plans offer access to providers with a record of delivering high-quality, efficient care. Since January 2021, we’ve been collaborating with select healthcare providers across the U.S. to make BlueHPN available to members. Anthem’s mission is to provide affordable, quality healthcare benefits to its members. This in-network only plan helps keep members’ healthcare costs more predictable and manageable. It is important to know that only in-network care is covered in the BlueHPN. Members in the BlueHPN cannot go to out-of-network doctors or hospitals, except in an urgent and/or emergent situation. If they see a provider for routine or non-urgent care outside the BlueHPN, they will not have coverage. If you are not participating in the Anthem High Performance network, you are also not participating in the BlueHPN. Recognizing BlueHPN membersYou and your staff can identify patients enrolled in BlueHPN plans by their member ID card. The BlueHPN name will be prominently displayed on the front of the member ID card, along with the BlueHPN suitcase logo, as shown below: 
Eligibility and benefitsBlueHPN does not offer coverage for out-of-network care with the exception of urgent and/or emergent services. This means that BlueHPN patients will receive full benefits from in-network BlueHPN providers. You can check BlueHPN plan member eligibility and benefits the same way you do today for Anthem High Performance members — Either submit a HIPAA 270 eligibility and benefit request transaction or contact Provider Services at the number on the back of the member’s ID card. Referrals to BlueHPN providersBlueHPN is a comprehensive network that includes a full range of providers, from primary care doctors and specialists to hospitals. Not all healthcare providers are included. To ensure your BlueHPN patients will have full benefits when they need to see a specialist or another healthcare provider, it’s important that you only recommend other BlueHPN healthcare providers. You can use the Find a Doctor/Find Care tool at https://anthem.com/find-care to identify BlueHPN healthcare providers by searching by the member’s ID or alpha prefix. This will help ensure your patients will be receiving care from healthcare providers who are also committed to providing high quality, cost-efficient care. Please make sure you and your office staff are checking network status when referring members to new providers. Formal physician-to-physician referrals are not required under BlueHPN plans, but out-of-network benefits are limited to urgent and/or emergent services only. That means referrals for non-emergency care to providers outside the BlueHPN network, including durable medical equipment and laboratory services, may be costly for your patients. Additional network informationMore than 60 large metropolitan areas have their own high-performance networks sponsored by local Anthem plans across the country, which gives national employers access to high quality, cost-efficient providers in these geographic areas. The California BlueHPN uses the existing Anthem High Performance network; therefore, you may see both local patients who have access to Anthem High Performance through the Anthem plan and patients traveling from other cities where BlueHPN products are offered. California-based employer-sponsored health plans with access to our California High Performance Network refer to the BlueHPN as Anthem High Performance. If you are not sure whether your practice is part of the California BlueHPN or Anthem High Performance, ask your office manager or business office or contact your provider relationship account manager. Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross and Anthem Blue Cross Life and Health Insurance Company are independent licensees of the Blue Cross Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. CABC-CM-051350-24-CPN50889 When we receive a corrected claim and it doesn’t have the original claim number, or the original claim number is not correctly entered, we are not able to process it because we’re not able to connect it to the original claim.
- For providers and their vendors (clearinghouses or billing services) submitting a corrected claim through EDI, we will send you a 277CA EDI Response Report acknowledging that we’ve received the submission, but are not able to process it:
- In this instance, you can either submit a new corrected claim with the original claim ID number or submit the corrected claim as an original claim if you do not have the original claim ID number.
- It is important that you submit proof of timely filing of the original claim when submitting a corrected claim so we can ensure the claim is processed according to the timely filing guidelines.
- For providers using Claims Status application on Availity.com, you will not be able to access the corrected claim if it was rejected on the 277CA EDI Response Report:
- In this instance, you can either submit a new corrected claim with the original claim ID number or submit the corrected claim as an original claim if you do not have the original claim ID number.
- It is important that you submit proof of timely filing of the original claim when submitting a corrected claim so we can ensure the claim is processed according to the timely filing guidelines.
We’ve also developed a training video that can help further in reducing duplicate claims along with a training guide called Making the Claims Process Work for You that can help you in properly submitting a corrected claim. Access the video and download the guide here. Provider information is required to view, but it will only occur the first time viewing this training.
If you have questions about submitting a corrected claim, reach out to your provider representative or work with your EDI vendor to ensure you are receiving the 277CA Response Report. Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross and Anthem Blue Cross Life and Health Insurance Company are independent licensees of the Blue Cross Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. CABC-CM-049144-23-CPN48099, CABC-CM-061596-24-CPN61590 Anthem provides coverage of the FDA-approved methods for women’s contraceptive services, sterilization procedures, and counseling, including: - Generic contraceptive drugs.
- Injectable contraceptive drugs and patches.
- Contraceptive devices such as diaphragms, intra uterine devices (IUDs), cervical caps and implants.
- Over-the-counter FDA-approved contraceptives for women as prescribed by a healthcare provider.
- Voluntary sterilization procedures for women.
- Education and counseling.
Important note about contraceptive drugsAnthem provides coverage for contraceptive services and will be covered at a $0 cost sharing when obtained from an in-network pharmacy. Some categories and classes of contraception do not have generics available and, in each of these categories, at least one brand name product is available at a $0 cost sharing. If the provider determines that a brand name drug with an available generic therapeutic equivalent is necessary because a generic therapeutic equivalent drug is not appropriate , the member may obtain coverage of the drug with a $0 cost sharing if a provider submits an Exception Request to receive prior approval to prescribe the contraceptive. Members can find additional information regarding these contraceptive benefits, including the Exception Request process, in the Evidence of Coverage and Disclosure Form. Cost sharing may vary depending on state laws and regulations. Evidence of Coverage and Disclosure Form: Exception request for a quantity, dose or frequency limitation, step therapy, or a drug not on the prescription drug list (including contraceptive drugs)If an exception is needed to limit to a quantity, dose or frequency limitation, to step therapy, or need a prescription drug that is not on the prescription drug list, the provider must complete a uniform prior authorization form and return it to us. The form can be found online at anthem.com/ca/provider or by calling the number listed on the back of the member ID card. If medical necessity has been determined, an exception will be granted. We will make a coverage decision within 72 hours of receiving your request. If we approve the exception request, coverage will be provided for the duration of your prescription, including refills. If we deny the request, you have the right to request an external review by an independent review organization (IRO). The IRO will make a coverage decision within 72 hours of receiving your request. If the IRO approves the request, coverage will be provided for the duration of your prescription, including refills. If the approved drug is a contraceptive drug, coverage of the drug will be provided at no cost to the member. The provider or member may also submit a request for a prescription drug that is not on the prescription drug list based on exigent circumstances. Exigent circumstances exist if suffering from a health condition that may seriously jeopardize life, health, or ability to regain maximum function, or if undergoing a current course of treatment using a drug not on the prescription drug list. We will make a coverage decision within 24 hours of receiving your request. If we approve the coverage of the drug, coverage of the drug will be provided for the duration of the prescription, (including refills) or duration of the exigency, as applicable. If the approved drug is a contraceptive drug, coverage of the drug will be provided at no cost to the member. If we deny coverage of the drug, the member has the right to request an external review by an IRO. The IRO will make a coverage decision within 24 hours of receiving your request. If the IRO approves the coverage of the drug, coverage of the drug will be provided for the duration of the exigency. The external exception review process is in addition to a member’s right to file a grievance or request an Independent Medical Review by the Department of Managed Health Care. If we or the IRO approve a drug that is a contraceptive drug, coverage of the drug will be provided at no cost to the member. Coverage of a drug approved as a result of your request or your doctor’s request for an exception will only be provided if you are a member enrolled under the plan. Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross and Anthem Blue Cross Life and Health Insurance Company are independent licensees of the Blue Cross Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. CABC-CM-051669-24 Anthem is thrilled to announce ON24®, a new platform for provider coding education and learning! As a valued Anthem network provider, we invite you to experience the new digital learning platform. You’ll simply register once to gain access to all the following: - Live webcasts: Learn from instructors and earn continuing education credits.
- On-demand videos: Watch past webcasts at your convenience.
- Interactive modules: Engage in learning activities and practice coding skills at your own pace.
- Coding guides: Download handy references for accurate and complete coding.
Join us on the new digital platform today and take your learning to the next level! To ensure the best experience, please copy and paste the following registration link into a Google Chrome browser and use the Chrome browser when you access the ON24 platform: https://gateway.on24.com/wcc/eh/4109315/category/127954/caanthem?partnerref=ProvidernewsAnthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross and Blue Cross of California Partnership Plan, Inc. are independent licensees of the Blue Cross Association. Blue Cross of California is contracted with L.A. Care Health Plan to provide Medi-Cal Managed Care services in Los Angeles County. Anthem is a registered trademark of Anthem Insurance Companies, Inc. CABC-CD-049929-24 Effective on June 30, 2024, the following Carelon Medical Benefits Management, Inc. Clinical Appropriateness Guideline updates for medical necessity review will apply for Anthem: - Genetic testing:
- Hereditary cancer testing
- Carrier screening in the prenatal setting and preimplantation genetic testing
- Genetic testing for inherited conditions
Existing precertification requirements have not changed. Please share this notice with other members of your practice and office staff. Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross and Blue Cross of California Partnership Plan, Inc. are independent licensees of the Blue Cross Association. Blue Cross of California is contracted with L.A. Care Health Plan to provide Medi-Cal Managed Care services in Los Angeles County. Anthem is a registered trademark of Anthem Insurance Companies, Inc. CABC-CD-050468-24-CPN49779 Summary: On December 11, 2023, and January 5, 2024, the Pharmacy and Therapeutic (P&T) Committee approved the following Clinical Criteria applicable to the medical drug benefit for Anthem. These policies were developed, revised, or reviewed to support clinical coding edits. Visit Clinical Criteria to search for specific policies. If you have questions or need additional information, use this email. Please see the explanation/definition for each category of Clinical Criteria below: - New: newly published criteria
- Revised: addition or removal of medical necessity requirements, new document number
- Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive
Please share this notice with other providers in your practice and office staff. Please note: - The Clinical Criteria listed below applies only to the medical drug benefits contained within the member’s medical policy. This does not apply to pharmacy services.
- This notice is meant to inform the provider of new or revised criteria that has been adopted by Anthem only. It does not include details regarding any authorization requirements. Authorization rules are communicated via a separate notice.
Effective date | Clinical Criteria number | Clinical Criteria title | New or revised | June 17, 2024 | *CC-0255 | Loqtorzi (toripalimab-tpzi) | New | June 17, 2024 | *CC-0256 | Rivfloza (nedosiran) | New | June 17, 2024 | *CC-0257 | Wainua (eplontersen) | New | June 17, 2024 | *CC-0185 | Oxlumo (lumasiran) | Revised | June 17, 2024 | *CC-0107 | Bevacizumab for Non-ophthalmologic Indications | Revised | June 17, 2024 | *CC-0002 | Colony Stimulating Factor Agents | Revised | June 17, 2024 | CC-0075 | Rituximab Agents for Non-Oncologic Indications | Revised | June 17, 2024 | CC-0213 | Voxzogo (vosoritide) | Revised | June 17, 2024 | CC-0124 | Keytruda (pembrolizumab) | Revised | June 17, 2024 | *CC-0110 | Perjeta (pertuzumab) | Revised |
Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross and Blue Cross of California Partnership Plan, Inc. are independent licensees of the Blue Cross Association. Blue Cross of California is contracted with L.A. Care Health Plan to provide Medi-Cal Managed Care services in Los Angeles County. Anthem is a registered trademark of Anthem Insurance Companies, Inc. CABC-CD-051275-24-CPN50531 The Medical Policies, Clinical Utilization Management (UM) Guidelines, and Third-Party Criteria below were developed and/or revised to support clinical coding edits. Note, several policies and guidelines were revised to provide clarification only and are not included. Existing precertification requirements have not changed. Please share this notice with other providers in your practice and office staff. To view a guideline, visit providers.anthem.com/ca > Resources > Provider Manuals, Policies & Guidelines > Medical Policies and Clinical UM Guidelines. Notes/updates:Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive: - ANC.00009 - Cosmetic and Reconstructive Services of the Trunk, Groin, and Extremities;
- Previously titled: Cosmetic and Reconstructive Services of the Trunk and Groin:
- Revised title to include “Extremities"
- Revised Position Statement regarding lipectomy or liposuction for lymphedema and lipedema
- DME.00011 - Electrical Stimulation as a Treatment for Pain and Other Conditions: Surface and Percutaneous Devices:
- Reformatted bullet points to letters
- Added lines to Investigational & Not Medically Necessary statement on electrical stimulation wound treatment device, electromagnetic wound treatment devices and pulsed electromagnetic field stimulation
- LAB.00011 - Selected Protein Biomarker Algorithmic Assays:
- Reformatted bullet points to letters
- Added IMMray® PanCan-d test to the Investigational & Not Medically Necessary statement
- LAB.00028 - Blood-based Biomarker Tests for Multiple Sclerosis, Previously titled: Serum Biomarker Tests for Multiple Sclerosis:
- Revised title
- Expanded scope of document from serum to blood-based biomarker testing for multiple sclerosis (MS)
- Revised Position Statement to indicate blood-based biomarker tests for multiple sclerosis are considered Investigational & Not Medically Necessary for all uses
- MED.00140 - Lentiviral Gene Therapy for Beta Thalassemia and Sickle Cell Disease; Previously Titled: Gene Therapy for Beta Thalassemia:
- Revised title
- Added Investigational & Not Medically Necessary statement on lovotibeglogene autotemcel
- MED.00144 - Gene Therapy for Duchenne Muscular Dystrophy:
- Outlines the Medically Necessary and Investigational & Not Medically Necessary criteria for the infusion of Delandistrogene moxeparvovec-rokl (ELEVIDYS)
- MED.00147 - Cellular Therapy Products for Allogeneic Stem Cell Transplantation:
- Outlines the Medically Necessary and Investigational & Not Medically Necessary criteria for the use of ex-vivo expansion of cord blood stem cell products
- SURG.00129 - Percutaneous Vertebral Disc and Vertebral Endplate Procedures:
- Removed the criteria examples for failed CPAP treatment
- Added definition for failed CPAP treatment
- SURG.00144 - Occipital and Sphenopalatine Ganglion Nerve Block Therapy for the Treatment of Headache and Neuralgia; Previously titled: Occipital Nerve Block Therapy for the Treatment of Headache and Occipital Neuralgia:
- Revised title
- Added Investigational & Not Medically Necessary statement for sphenopalatine ganglion nerve blocks
- TRANS.00041 - Histological Analysis using Microarray Gene Expression Profiling for Kidney Allograft Injury or Rejection:
- Histological analysis using microarray gene expression profiling is considered Investigational & Not Medically Necessary for detection of allograft injury or rejection in kidney transplant recipients
- CG-MED-39 - Bone Mineral Density Testing Measurement:
- Added phrase “using Dual-X-Ray Absorptiometry” to bullets I and III of Medically Necessary criteria and to bullets I and IV of Not Medically Necessary criteria
- Added Not Medically Necessary position statement for bone strength and fracture risk assessment using imaging scans other than DXA
- CG-MED-95 - Transanal Irrigation:
- Outlines the Medically Necessary and Not Medically Necessary criteria for transanal irrigation
- CG-OR-PR-05 - Myoelectric Upper Extremity Prosthetic Devices:
- Revised formatting of Medically Necessary section
- Added Repair and Replacement criteria to Clinical Indications section
- Added new Not Medically Necessary statement regarding enhanced dexterity prosthetic arm myoelectric upper extremity prosthetic devices
- Added new Medically Necessary and Not Medically Necessary criteria for device repair and replacement.
- CG-SURG-61 - Cryosurgical, Radiofrequency, Microwave or Laser Ablation to Treat Solid Tumors Outside the Liver; Previously titled: Cryosurgical, Radiofrequency or Laser Ablation to Treat Solid Tumors Outside the Liver:
- Revised title
- Added microwave ablation to the Clinical Indications
- Added cryoablation and microwave ablation to the Medically Necessary indications for NSCLC and malignant tumors that have metastasized to the lung
- Added Not Medically Necessary statements regarding focal cryoablation of the prostate and microwave ablation for all other indications
- Revised Medically Necessary indication for cryoablation of the prostate to whole gland cryoablation of the prostate
- Reordered clinical indications to be based on clinical condition rather than ablative technique
Medical PoliciesOn August 10, 2023, the Medical Policy and Technology Assessment Committee (MPTAC) approved the following Medical Policies applicable to Anthem. These medical policies take effect April 5, 2024. Publish date | Medical Policy number | Medical Policy title | New or revised | 9/27/2023 | *ANC.00009 | Cosmetic and Reconstructive Services of the Trunk, Groin, and Extremities Previously titled: Cosmetic and Reconstructive Services of the Trunk and Groin | Revised | 9/27/2023 | *DME.00011 | Electrical Stimulation as a Treatment for Pain and Other Conditions: Surface and Percutaneous Devices | Revised | 9/27/2023 | *LAB.00011 | Selected Protein Biomarker Algorithmic Assays | Revised | 9/27/2023 | *LAB.00028 | Blood-based Biomarker Tests for Multiple Sclerosis Previously titled: Serum Biomarker Tests for Multiple Sclerosis | Revised | 9/27/2023 | *MED.00140 | Lentiviral Gene Therapy for Beta Thalassemia and Sickle Cell Disease Previously Titled: Gene Therapy for Beta Thalassemia | Revised | 9/27/2023 | *MED.00144 | Gene Therapy for Duchenne Muscular Dystrophy | New | 9/27/2023 | *MED.00147 | Cellular Therapy Products for Allogeneic Stem Cell Transplantation | New | 9/27/2023 | SURG.00052 | Percutaneous Vertebral Disc and Vertebral Endplate Procedures | Revised | 9/27/2023 | *SURG.00129 | Oral, Pharyngeal and Maxillofacial Surgical Treatment for Obstructive Sleep Apnea or Snoring | Revised | 9/27/2023 | *SURG.00144 | Occipital and Sphenopalatine Ganglion Nerve Block Therapy for the Treatment of Headache and Neuralgia Previously titled: Occipital Nerve Block Therapy for the Treatment of Headache and Occipital Neuralgia | Revised | 9/27/2023 | TRANS.00039 | Portable Normothermic Organ Perfusion Systems | Revised | 9/27/2023 | *TRANS.00041 | Histological Analysis using Microarray Gene Expression Profiling for Kidney Allograft Injury or Rejection | New |
Clinical UM GuidelinesOn August 10, 2023, the MPTAC approved the following Clinical UM Guidelines applicable to Anthem. These guidelines were adopted by the medical operations committee for Medicare Advantage members on September 28, 2023. These guidelines take effect April 5, 2024. Publish date | Clinical UM Guideline number | Clinical UM Guideline title | New or revised | 9/27/2023 | *CG-MED-39 | Bone Mineral Density Testing Measurement | Revised | 9/27/2023 | CG-MED-83 | Site of Care: Specialty Pharmaceuticals | Revised | 9/27/2023 | *CG-MED-95 | Transanal Irrigation | New | 9/27/2023 | *CG-OR-PR-05 | Myoelectric Upper Extremity Prosthetic Devices | Revised | 9/27/2023 | CG-OR-PR-08 | Microprocessor Controlled Lower Limb Prosthesis | Conversion New | 9/27/2023 | CG-OR-PR-09 | Microprocessor Controlled Knee-Ankle-Foot Orthosis | Conversion New | 9/27/2023 | CG-SURG-01 | Colonoscopy | Revised | 9/27/2023 | *CG-SURG-61 | Cryosurgical, Radiofrequency, Microwave or Laser Ablation to Treat Solid Tumors Outside the Liver Previously titled: Cryosurgical, Radiofrequency or Laser Ablation to Treat Solid Tumors Outside the Liver | Revised | 9/27/2023 | CG-SURG-79 | Implantable Infusion Pumps | Revised | 9/27/2023 | CG-SURG-83 | Bariatric Surgery and Other Treatments for Clinically Severe Obesity | Revised |
Anthem BC Health Insurance Company is the trade name of Anthem Insurance Companies, Inc. Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross, Anthem Blue Cross Life and Health Insurance Company, and Anthem BC Health Insurance Company are independent licensees of the Blue Cross Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. CABC-CR-049963-24-CPN49653 Effective for dates of service on and after July 1, 2024, the following codes will require prior authorization through Carelon Medical Benefits Management, Inc.: CPT® code | Description | 0403U | Oncology (prostate), mRNA, gene expression profiling of 18 genes, first-catch post-digital rectal examination urine (or processed first-catch urine), algorithm reported | 0411U | Psychiatry (for example, depression, anxiety, attention deficit hyperactivity disorder [ADHD]), genomic analysis panel, variant analysis of 15 genes, including deletion/duplication | 0419U | Neuropsychiatry (for example, depression, anxiety), genomic sequence analysis panel, variant analysis of 13 genes, saliva or buccal swab, report of each gene phenotype | 0262U | Oncology (solid tumor), gene expression profiling by real-time RT-PCR of 7 gene pathways (ER, AR, PI3K, MAPK, HH, TGFB, Notch), formalin-fixed paraffin-embedded (FFPE) | 0405U | Oncology (pancreatic), 59 methylation haplotype block markers, next-generation sequencing, plasma, reported as cancer signal detected or not detected | 0409U | Oncology (solid tumor), DNA (80 genes) and RNA (36 genes), by next-generation sequencing from plasma, including single nucleotide variants, insertions/deletions, copy number | 0410U | Oncology (pancreatic), DNA, whole genome sequencing with 5-hydroxymethylcytosine enrichment, whole blood or plasma, algorithm reported as cancer detected or not detected | 0413U | Oncology (hematolymphoid neoplasm), optical genome mapping for copy number alterations, aneuploidy, and balanced/complex structural rearrangements, DNA from blood or bone marrow | 0414U | Oncology (lung), augmentative algorithmic analysis of digitized whole slide imaging for 8 genes (ALK, BRAF, EGFR, ERBB2, MET, NTRK1-3, RET, ROS1), and KRAS G12C and PD-L1 | 0417U | Rare diseases (constitutional/heritable disorders), whole mitochondrial genome sequence with heteroplasmy detection and deletion analysis, nuclear-encoded mitochondrial gene |
As a reminder, ordering and servicing providers may submit prior authorization requests to Carelon Medical Benefits Management in one of several ways: - Access Carelon Medical Benefits Management’s ProviderPortalSM directly at providerportal.com:
- Online access is available 24/7 to process orders in real-time and is the fastest and most convenient way to request authorization.
- Access the Availity website at Availity.com.
If you have questions related to guidelines, please contact Carelon Medical Benefits Management via email at MedicalBenefitsManagement.guidelines@Carelon.com. Additionally, you may access and download a copy of the current and upcoming guidelines here. Carelon Medical Benefits Management, Inc. is an independent company providing utilization management services on behalf of the health plan. Anthem BC Health Insurance Company is the trade name of Anthem Insurance Companies, Inc. Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross, Anthem Blue Cross Life and Health Insurance Company, and Anthem BC Health Insurance Company are independent licensees of the Blue Cross Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. CABC-CR-051633-24-CPN51333 Effective June 1, 2024, prior authorization (PA) requirements will change for the following code(s). The medical code(s) listed below will require PA by Anthem Blue Cross for Medi-Cal members. Federal and state law, as well as state contract language and Centers for Medicare & Medicaid Services guidelines, including definitions and specific contract provisions/exclusions, take precedence over these PA rules and must be considered first when determining coverage. Non-compliance with new requirements may result in denied claims. Prior authorization requirements will be added for the following code(s):Code | Description | 64505 | Injection, Anesthetic Agent; Sphenopalatine Ganglion |
To request PA, you may use one of the following methods: - Web: Once logged in to Availity Essentials at Availity.com.
- Fax: 800-754-4708
- Phone: Medi-Cal: 888-831-2246
Not all PA requirements are listed here. Detailed PA requirements are available to providers on providers.anthem.com/ca on the Resources tab or for contracted providers by accessing Availity.com. Providers may also call one of the following Customer Care Centers for assistance with PA requirements: - Outside Los Angeles County: 800-407-4627
- Inside Los Angeles County: 888-285-7801
UM AROW A2023M0966 Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross and Blue Cross of California Partnership Plan, Inc. are independent licensees of the Blue Cross Association. Blue Cross of California is contracted with L.A. Care Health Plan to provide Medi-Cal Managed Care services in Los Angeles County. Anthem is a registered trademark of Anthem Insurance Companies, Inc. CABC-CD-049842-24-CPN49513 Effective July 1, 2024, prior authorization (PA) requirements will change for the following code(s). The medical code(s) listed below will require PA by Anthem for Medicare Advantage members. Federal and state law, as well as state contract language and Centers for Medicare & Medicaid Services guidelines (including definitions and specific contract provisions/exclusions), take precedence over these precertification rules and must be considered first when determining coverage. Non-compliance with new requirements may result in denied claims. Prior authorization requirements will be added for the following code(s): Code | Description | 0088U | Transplantation medicine (kidney allograft rejection), microarray gene expression profiling of 1494 genes, utilizing transplant biopsy tissue, algorithm reported as a probability score for rejection Molecular Microscope® MMDx—Kidney, Kashi Clinical Laboratories | 0342U | Oncology (pancreatic cancer), multiplex immunoassay of C5, C4, cystatin C, factor B, osteoprotegerin (OPG), gelsolin, IGFBP3, CA125 and multiplex electrochemiluminescent immunoassay (ECLIA) for CA19-9, serum, diagnostic algorithm reported qualitatively as positive, negative, or borderline | 0361U | Neurofilament light chain, digital immunoassay, plasma, quantitative Neurofilament Light Chain (NfL), Mayo Clinic, Mayo Clinic | 0390U | Obstetrics (preeclampsia), kinase insert domain receptor (KDR), Endoglin (ENG), and retinol-binding protein 4 (RBP4), by immunoassay, serum, algorithm reported as a risk score PEPredictDx, OncoOmicsDx Laboratory, mProbe | 0407U | Nephrology (diabetic chronic kidney disease [CKD]), multiplex electrochemiluminescent immunoassay (ECLIA) of soluble tumor necrosis factor receptor 1 (sTNFR1), soluble tumor necrosis receptor 2 (sTNFR2), and kidney injury molecule 1 (KIM-1) combined with clinical data, plasma, algorithm reported as risk for progressive decline in kidney function IntelxDKD™, Renalytix Inc, Renalytix Inc, NYC, NY | 0412U | Beta amyloid, Aβ42/40 ratio, immunoprecipitation with quantitation by liquid chromatography with tandem mass spectrometry (LC-MS/MS) and qualitative ApoE isoform-specific proteotyping, plasma combined with age, algorithm reported as presence or absence of brain amyloid pathology PrecivityAD® blood test, C2N Diagnostics LLC, C2N Diagnostics LLC | 0494T | Surgical preparation and cannulation of marginal (extended) cadaver donor lung(s) to ex vivo organ perfusion system, including decannulation, separation from the perfusion system, and cold preservation of the allograft prior to implantation, when performed | 0495T | Initiation and monitoring marginal (extended) cadaver donor lung(s) organ perfusion system by physician or qualified health care professional, including physiological and laboratory assessment (for example, pulmonary artery flow, pulmonary artery pressure, left atrial pressure, pulmonary vascular resistance, mean/peak and plateau airway pressure, dynamic compliance and perfusate gas analysis), including bronchoscopy and X ray when performed; first two hours in sterile field | 64505 | Injection, anesthetic agent; sphenopalatine ganglion [when specified as a therapeutic nerve block] |
Not all PA requirements are listed here. Detailed PA requirements are available to providers on anthem.com/medicareprovider on the Resources tab or for contracted providers by accessing Availity.com. Providers may also call Provider Services at the number on the back of the patient’s member ID card for assistance with PA requirements. UM AROW A2023M0970 Anthem BC Health Insurance Company is the trade name of Anthem Insurance Companies, Inc. Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross, Anthem Blue Cross Life and Health Insurance Company, and Anthem BC Health Insurance Company are independent licensees of the Blue Cross Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BC-CR-049938-24-CPN49553 Effective for dates of service on and after July 1, 2024, the specialty Medicare Part B drugs listed in the table below will be included in our precertification review process. Federal and state law, as well as state contract language and CMS guidelines (including definitions and specific contract provisions/exclusions), take precedence over these precertification rules and must be considered first when determining coverage. Noncompliance with new requirements may result in denied claims. HCPCS or CPT® codes | Medicare Part B drugs | J3490, J3590, J9999, C9399 | Elrexfio (elranatamab-bcmm) | J3490, J3590 | Eylea HD (aflibercept) | J3490, J3590 | Pombiliti (cipaglucosidase alfa-atga) | J3490, J3590, J9999, C9399 | Talvey (talquetamab-tgvs) | J3490, J3590 | Tyruko (natalizumab-sztn) | J3590, C9399 | Veopoz (pozelimab-bbfg) | J3490 | Ycanth (cantharidin) |
Anthem BC Health Insurance Company is the trade name of Anthem Insurance Companies, Inc. Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross, Anthem Blue Cross Life and Health Insurance Company, and Anthem BC Health Insurance Company are independent licensees of the Blue Cross Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. CABC-CR-054036-24-CPN53511 Visit the Drug Lists page on our website at anthem.com/ca/ms/pharmacyinformation/home.html for more information about: - Copayment/coinsurance requirements and their applicable drug classes.
- Drug lists and changes.
- Prior authorization criteria.
- Procedures for generic substitution.
- Therapeutic interchange.
- Step therapy or other management methods subject to prescribing decisions.
- Any other requirements, restrictions, or limitations that apply to using certain drugs.
The commercial and exchange drug lists are posted to the website quarterly on the first day of the month in January, April, July, and October. To locate the exchange, select Formulary and Pharmacy Information and scroll down to Select Drug Lists. This drug list is also reviewed and updated regularly as needed. Federal Employee Program pharmacy updates and other pharmacy related information may be accessed at fepblue.org > Pharmacy Benefits. Please call provider services to request a copy of the pharmaceutical information available online if you do not have internet access. Through our efforts, we are committed to reducing administrative burden because we value you, our care provider partner. Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross and Anthem Blue Cross Life and Health Insurance Company are independent licensees of the Blue Cross Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. CABC-CM-053184-24-CPN53029 Effective July 1, 2024, the following medication codes will require prior authorization. Please note, inclusion of a National Drug Code (NDC) on your medical claim is necessary for claims processing. Visit the Clinical Criteria website to search for the specific Clinical Criteria listed below. Clinical Criteria | HCPCS or CPT® code(s) | Drug name | CC-0248 | C9165, J3490 J3590, J9999 | Elrexfio (elranatamab-bcmm) | CC-0068 | C9399, J3590 | Ngenla (somatrogon-ghla) | CC-0018 | J3490, J3590 | Pombiliti (cipaglucosidase alfa-atga) | CC-0249 | C9163, J3490, J3590, J9999 | Talvey (talquetamab-tgvs) | CC-0020 | J3490, J3590 | Tyruko (natalizumab-sztn) | CC-0250 | C9399, J3590 | Veopoz (pozelimab-bbfg) | CC-0251 | C9164, J3490 | Ycanth (cantharidin) |
What if I need assistance?If you have questions about this communication or need assistance with any other item, contact your local provider relationship management representative or call Provider Services at one of the following phone numbers: - Outside of Los Angeles County: 800-407-4627
- Los Angeles County: 888-285-7801
Note: Prior authorization requests for certain medications may require additional documentation to determine medical necessity. Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross and Blue Cross of California Partnership Plan, Inc. are independent licensees of the Blue Cross Association. Blue Cross of California is contracted with L.A. Care Health Plan to provide Medi-Cal Managed Care services in Los Angeles County. Anthem is a registered trademark of Anthem Insurance Companies, Inc. CABC-CD-051164-24-CPN50821 Effective July 1, 2024, the following medication codes will require prior authorization. Please note, inclusion of a National Drug Code (NDC) on your medical claim is necessary for claims processing. Visit the Clinical Criteria website to search for the specific Clinical Criteria listed below. Clinical Criteria | HCPCS or CPT® code(s) | Drug name | CC-0241 | J3490, J3590 | Elfabrio (pegunigalsidase alfa-iwxj) | CC-0242 | C9399, J3490, J3590, J9999 | Epkinly (epcoritamab-bysp) | CC-0237 | J3490, J3590 | Qalsody (tofersen) | CC-0243 | J3490, J3590 | Vyjuvek (beremagene geperpavec) | CC-0240 | J9999 | Zynyz (retifanlimab-dlwr) |
What if I need assistance?
If you have questions about this communication or need assistance with any other item, contact your local Provider Relationship Management representative or call Provider Services at the following phone numbers: outside L.A. County at 800-407-4627 or L.A. County at 888-285-7801. Note: Prior authorization requests for certain medications may require additional documentation to determine medical necessity. Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross and Blue Cross of California Partnership Plan, Inc. are independent licensees of the Blue Cross Association. Blue Cross of California is contracted with L.A. Care Health Plan to provide Medi-Cal Managed Care services in Los Angeles County. Anthem is a registered trademark of Anthem Insurance Companies, Inc. CABC-CD-047739-23-CPN47364 Only Electronic Clinical Data Systems (ECDS) reporting will be used for this measure. Measure descriptionThe percentage of members 45 to 75 years of age who had appropriate screening for colorectal cancer (revised the age range from 50 to 75 years of age to 45 to 75 years of age). What we are looking for in provider recordsDocumentation in the medical record indicating the date when the colorectal cancer screening was performed and result or finding of one or more of the following: - A pathology report that indicates the type of screening (for example, colonoscopy, flexible sigmoidoscopy) and the date the screening was performed
- Documentation of a Fecal Occult Blood Test (FOBT) during the measurement year (2024)
- Documentation of a flexible sigmoidoscopy during the measurement year or the four years prior to the measurement year (January 1, 2020, to December 31, 2024)
- Documentation of a colonoscopy during the measurement year or the nine years prior to the measurement year (January 1, 2015, to December 31, 2024)
- Documentation of a CT colonography during the measurement year or the four years prior to the measurement year (January 1, 2020, to December 31, 2024)
- Documentation of Stool DNA (sDNA) with FIT test during the measurement year or two years prior to the measurement year (January 1, 2022, to December 31, 2024)
- Documentation of members who are diagnosed with colorectal cancer on or before December 31, 2024
- Documentation of a total colectomy on or before December 31, 2024 (documentation must state total, not partial)
- Evidence of hospice services in 2024
- Evidence patient expired prior to January 1, 2025
Helpful hints: - Recommend colorectal cancer screening to all patients 45 to 75 years of age.
- If a patient is hesitant, discuss different screening options.
- Educate that screening is recommended, even if there is no family history of colon cancer.
HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA). Anthem Blue Cross is the trade name of Blue Cross of California. Anthem BC Health Insurance Company is the trade name of Anthem Insurance Companies, Inc. Anthem Blue Cross, Anthem Blue Cross Life and Health Insurance Company, Anthem BC Health Insurance Company, and Blue Cross of California Partnership Plan, Inc. are independent licensees of the Blue Cross Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.
Blue Cross of California is contracted with L.A. Care Health Plan to provide Medi-Cal Managed Care services in Los Angeles County. CABC-CDCRCM-050271-24-CPN49873 |